A discovery by researchers at the Texas A&M College of Medicine could lead to new therapies to prevent the virus from proliferating in the human body.
The immune system is a complex network of cells and proteins that is designed to fight off infection and disease, especially those like the coronavirus, or SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the official name of the virus strain that causes coronavirus disease (COVID-19). Previous to this name being adopted, it was commonly referred to as the 2019 novel coronavirus (2019-nCoV), the Wuhan coronavirus, or the Wuhan virus.”>SARS-CoV-2, that can cause numerous issues in the human body. But many individuals are still at risk of being infected with the coronavirus, letting it replicate in the body and further transmitting to other individuals.
The underlying mechanism of how SARS-CoV-2 escapes from the immune system has been poorly understood. However, researchers from the Texas A&M University College of Medicine and Hokkaido UniversityFounded in 1876 as Sapporo Agricultural College, Hokkaido University (Hokkaidō daigaku or Hokudai) is a Japanese national university in Sapporo, Hokkaido. It was selected as a Top Type university of Top Global University Project by the Japanese government.”>Hokkaido University have recently discovered a major mechanism that explains how SARS-CoV-2 can escape from the immune system and replicate in the human body. Their findings were recently published in the journal Nature Communications.
“We found that the SARS-CoV-2 virus carries a suppressive gene that acts to inhibit a human gene in the immune system that is essential for destroying infected cells,” said Dr. Koichi Kobayashi, adjunct professor at the College of Medicine and lead author of the paper.
Naturally, the cells in a human’s immune system are able to control virus infection by destroying infected cells so that the virus cannot be replicated. The gene that is essential in executing this process, called NLRC5, regulates major histocompatibility complex (MHC) class I genes, which are genes that create a pathway that is vital in providing antiviral immunity. Kobayashi and his colleagues discovered this in 2012.
“During infection, the amount and activity of NLRC5 gene become augmented in order to boost our ability of eradication of viruses,” Kobayashi said. “We discovered that the reason why SARS-CoV-2 can replicate so easily is because the virus carries a suppressive gene, called ORF6, that acts to inhibit the function of NLRC5, thus inhibiting the MHC class I pathway as well.”
Kobayashi, who holds a joint appointment as a professor at Hokkaido University in Japan, collaborated with Paul de Figueiredo, associate professor in the Department of Microbial Pathogenesis and Immunology at the College of Medicine, on this paper.
Kobayashi and his team’s discovery shed light on the mechanism to how SARS-CoV-2 can replicate in the human body and can potentially lead to the development of new therapeutics to prevent the coronavirus from escaping the immune system and replicating in the body.
Although the introduction of COVID-19First identified in 2019 in Wuhan, China, Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has spread globally, resulting in the 2019–20 coronavirus pandemic.”>COVID-19 vaccines, such as the Pfizer and Moderna vaccines, can lower an individual’s chance of contracting the virus, there is currently no permanent therapy that can entirely prevent a human from contracting SARS-CoV-2.
“We hope that this new discovery will allow us to develop a new drug that can block this gene so our immune system will be able to fight off the coronavirus for good,” de Figueiredo said.
Reference: “SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis” by Ji-Seung Yoo, Michihito Sasaki, Steven X. Cho, Yusuke Kasuga, Baohui Zhu, Ryota Ouda, Yasuko Orba, Paul de Figueiredo, Hirofumi Sawa and Koichi S. Kobayashi, 15 November 2021, Nature Communications.